Centric Health Announces 2019 Third Quarter Results

Adjusted EBITDA from Specialty Pharmacy more than triples compared to prior year

TORONTO, Nov. 11, 2019 /CNW/ - Centric Health Corporation ("Centric Health" or "the Company") (TSX: CHH), one of Canada's leading healthcare services companies, today reported its financial results for the third quarter ended September 30, 2019.

Highlights for the Third Quarter

  • Specialty Pharmacy revenue increased 12.4% to $31.4 million;
  • Average number of beds serviced increased 7.7% to 31,281;
  • Specialty Pharmacy Adjusted EBITDA1 increased 204.1% to $4.0 million;
  • Specialty Pharmacy Adjusted EBITDA margin increased to 12.9% vs. 4.8% in the third quarter of 2018;
  • Entered into a definitive agreement on August 9, 2019 to sell its Surgical and Medical Centres division to Kensington Private Equity Fund for a cash purchase price of $35 million, with the sale expected to close before the end of November 2019; and
  • Entered into a binding term sheet for a private placement of common shares and unsecured convertible debentures for gross proceeds of up to $37.7 million, announced on September 30, 2019.

Highlights Subsequent to Quarter-End

  • Appointed Andrew Mok as the Chief Financial Officer of the Company, after having served as interim CFO since November 2018.

"Our momentum continued in the third quarter, with strong growth in revenue and beds serviced, and significant growth in Adjusted EBITDA for our core Specialty Pharmacy business," said David Murphy, President and Chief Executive Officer of Centric Health. "The quarter was also an eventful and successful one as it relates to strengthening our balance sheet, as we announced both the sale of our Surgical and Medical Centres division and a large private placement.  With these milestones and our strategic transformation substantially completed, we have significantly improved our ability to capitalize on organic growth and acquisition opportunities in the Canadian institutional pharmacy sector."


Revenue from Specialty Pharmacy for the third quarter increased 12.4% to $31.4 million compared to the same period in the prior year as a result of continued growth in the average number of beds serviced during the quarter and the impact of revenue initiatives from the 2018 Business Re-Engineering Plan.

Adjusted EBITDA from Specialty Pharmacy increased 204.1% to $4.0 million for the third quarter compared to the same period in the prior year. The increase was due to higher revenue, the impact of the Business Re-Engineering Plan, and operational efficiencies resulting from increased scale as a higher average number of beds were serviced compared to the prior period. The impact of IFRS 16 for the quarter was an increase to Adjusted EBITDA from Specialty Pharmacy of $0.5 million. Adjusted EBITDA margin from Specialty Pharmacy was 12.9% for the quarter (11.3% excluding the impact of IFRS 16).

Selected Financial Information

(Thousands of Canadian dollars except per
share amounts and percentages)

For the three month periods
ended September 30,

For the nine month periods
ended September 30,









Revenue from Specialty Pharmacy





Adjusted EBITDA1 from Specialty Pharmacy





Adjusted EBITDA margin from Specialty Pharmacy





Corporate office costs





Adjusted EBITDA from continuing operations





Adjusted EBITDA Margin from continuing operations





Adjusted EBITDA





Per share - Basic2 and Diluted2





Adjusted EBITDA Margin





Net loss





Per share - Basic2 and Diluted2





Cash provided by operations





Total Assets





Total Liabilities





1 See "Non-IFRS Measures" below

2Basic and diluted earnings per share is based on the profit or loss attributable to shareholders of Centric Health Corporation


The Company's 2019 financial results include the impact of IFRS 16, a substantial change to lease accounting standards, effective January 1, 2019. Centric Health adopted IFRS 16 using the modified retrospective approach and the Company's comparative information was not restated.  As a result, the comparability of the Company's 2019 Adjusted EBITDA to periods prior to January 1, 2019 is impacted.

Corporate office expenses were lower for the quarter by 10.1% at $1.2 million compared to the same period in the prior year, with the variance being primarily due to labour savings realized in the current year.

Adjusted EBITDA from continuing operations was $2.8 million for the third quarter compared to a loss of $42 thousand for the same period in the prior year. The overall impact to Adjusted EBITDA from continuing operations from the adoption of IFRS 16 was an increase of $0.5 million for the quarter.


During the three and nine month periods ended September 30, 2019, the Company disposed of the operating assets of its retail pharmacy operations in Grande Prairie, AB and Medicine Hat, AB. The results of these operations have been included as part of discontinued operations on the consolidated statement of income and comprehensive income. As required under IFRS, the Company classified its former Surgical and Medical Centres segment as assets held for sale and have presented its current and prior year results as discontinued operations. Revenue and Adjusted EBITDA from discontinued operations were $8.9 million and a loss of $0.1 million, for the third quarter, respectively.  The impact of the transition to IFRS 16 in discontinued operations was an increase to Adjusted EBITDA of $0.4 million for the quarter.


Centric Health will host a conference call, including a slide presentation, to discuss its third quarter financial results on Tuesday, November 12, 2019 at 8:30 a.m. (ET).

Telephone Dial-In Access Information

To access the conference call by telephone, dial 647-427-7450 or 1-888-231-8191.  Please connect approximately 10 minutes prior to the beginning of the call to ensure participation.  Those participating in the conference call by telephone can view the slide presentation by accessing the online webcast (see instructions below) and choosing the Non-Streaming Audio option.

Webcast Access Information

A live webcast of the conference call, including the slide presentation, will be available on the Events and Presentations page of the Investors section of the Company's web site (http://www.centrichealth.ca/investors/events-and-presentations.html).  Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. To view the webcast presentation with slides, please choose either the Real Streaming Audio or Windows Streaming Audio option.

Archive Access Information

The conference call will be archived for replay by telephone until Tuesday, November 19, 2019 at midnight.  To access the archived conference call, dial 416-849-0833 or 1-855-859-2056 and enter the reservation number 1790987.

The webcast with slide presentation will be archived for 90 days on the Events and Presentations page of the Investors section of the Company's web site (http://www.centrichealth.ca/investors/events-and-presentations.html).

For further information, please refer to the Company's complete filings at www.sedar.com.


Centric Health's vision is to be the leading provider of pharmacy and other healthcare services to Canadian seniors. The Company is one of Canada's leading, and most trusted providers of comprehensive Specialty Pharmacy services and solutions to seniors. We operate a large national network of pharmacy fulfilment centres that deliver high-volume solutions for the cost-effective supply of chronic medication and other specialty clinical pharmacy services, serving more than 31,000 residents in over 460 seniors communities (long-term care, retirement homes, and assisted living facilities) nationally.

With services that address the growing demand within the Canadian healthcare system, Centric Health's unparalleled national care delivery platform provides significant potential for future expansion and growth.


This press release contains statements that may constitute "forward-looking statements" within the meaning of applicable Canadian securities legislation.  These forward-looking statements include, among others, statements regarding the Company's business strategy, plans and other expectations, beliefs, goals, objectives, information and statements about possible future events. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate" or similar expressions suggesting future outcomes or events. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management.

Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by such statements. Factors that could cause such differences include the Company's liquidity and capital requirements, government regulation and funding, the highly competitive nature of the Company's industry, reliance on contracts with key customers and other risk factors described from time to time in the reports and disclosure documents filed by the Company with Canadian securities regulatory agencies and commissions. These and other factors should be considered carefully and readers should not place undue reliance on the Company's forward-looking statements. As a result of the foregoing and other factors, no assurance can be given as to any such future results, levels of activity or achievements and neither the Company nor any other person assumes responsibility for the accuracy and completeness of these forward-looking statements. The factors underlying current expectations are dynamic and subject to change.


This press release includes certain measures which have not been prepared in accordance with IFRS such as EBITDA, Adjusted EBITDA, Adjusted EBITDA margin and Adjusted EBITDA per share. These non-IFRS measures are not recognized under IFRS and, accordingly, shareholders are cautioned that these measures should not be construed as alternatives to net income determined in accordance with IFRS. The non-IFRS measures presented are unlikely to be comparable to similar measures presented by other issuers.

The Company defines EBITDA as earnings before depreciation and amortization, interest expense, amortization of lease incentives, and income tax expense (recovery).  Adjusted EBITDA is defined as EBITDA before transaction and restructuring costs, changes in the fair value of the contingent consideration liability, impairments, stock based compensation expense, change in fair value of derivative financial instruments and gain on disposal of property and equipment recognized in the statement of income. Adjusted EBITDA margin is defined as Adjusted EBITDA divided by revenue. Adjusted EBITDA per share is defined as Adjusted EBITDA divided by the weighted outstanding shares on both a basic and diluted basis. The Company believes that Adjusted EBITDA is a meaningful financial metric as it measures cash generated from operations which the Company can use to fund working capital requirements, service interest and principal debt repayments and fund future growth initiatives.  The Company's agreements with senior lenders are structured with certain financial performance covenants which includes Adjusted EBITDA as a key component of the covenant calculations. EBITDA and Adjusted EBITDA are not recognized measures under IFRS

SOURCE Centric Health Corporation

For further information: David Murphy, President and Chief Executive Officer, Centric Health Corporation, 416-927-8400; Andrew Mok, Chief Financial Officer, Centric Health Corporation, 416-927-8400